Organogenesis: Clinical Win Re-Frames 2026 — A Tactical Long with Defined Risk Control
Organogenesis announced on 04/06/2026 that its randomized controlled trial of PuraPly AM met the 12‑week wound closure primary endpoint. At a market cap near $295M and an EV of $245M, the shares look attractively priced given the binary clinical overhang is now reduced. This is a tactical long for a mid‑term rebound with a clearly defined entry at …